Spero Therapeutics, Inc.SPROEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| OF ABOVE PERSONS | 6.90% | 3.8M | ▼ -1.20pp | 2024-11-14 |
Insider Transactions
Net 90d: −$393.2K · buys $0 / sells $393.2KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-06 | Timothy Keutzer | Chief Operating Officer | Sell (open market) | 18.7K | $2.36 | $44.0K |
| 2026-02-06 | Esther Rajavelu | See Remarks | Sell (open market) | 37.1K | $2.36 | $87.6K |
| 2026-02-06 | Esther Rajavelu | See Remarks | Sell (open market) | 50.8K | $2.36 | $119.9K |
| 2026-02-04 | Timothy Keutzer | Chief Operating Officer | Sell (open market) | 3.5K | $2.24 | $7.8K |
| 2026-02-03 | Timothy Keutzer | Chief Operating Officer | Sell (open market) | 24.2K | $2.14 | $51.8K |
| 2026-02-02 | Timothy Keutzer | Chief Operating Officer | Grant | 68.0K | $0.00 | $0 |
| 2026-02-02 | Timothy Keutzer | Chief Operating Officer | Sell (open market) | 18.9K | $2.20 | $41.6K |
| 2026-02-02 | Esther Rajavelu | See Remarks | Grant | 249.0K | $0.00 | $0 |
| 2026-02-02 | Esther Rajavelu | See Remarks | Sell (open market) | 18.4K | $2.20 | $40.6K |
1–9 of 9